Ulcerative Colitis: vedolizumab out performs adalimumab for clinical remission and endoscopic improvement

The IKBFU center for clinical research scientists have participated in the international VARSITY clinical research study, the world's first study aimed at finding the most effective drug among anti-inflammatory drugs for the treatment of ulcerative colitis. The results, ‘Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis’, were published in The New England Journal of Medicine.

Study finds Cook Medical’s Hemospray is 98% successful in treating GI bleeding

A new, multi-centre study on Cook Medical’s Hemospray Endoscopic Hemostat device has revealed that the use of Hemospray demonstrated a more than 98% successful hemostasis rate, while the 30-day rebleeding rate was 10%. The results, ‘Successful hemostasis of active lower GI bleeding using a hemostatic powder as monotherapy, combination therapy, or rescue therapy’, were published in the April 2019 edition of Gastrointestinal Endoscopy.

New approach to bowel cancer analysis could lead to better prognosis for patients

Researchers from Queen’s University have demonstrated how a precise integration of the results of both pathological and molecular analysis of tumour and normal tissue from the bowel can ensure a correct interpretation of the data, providing a more accurate result that can underpin better treatment options for bowel cancer patients. The paper, ‘Epithelial-to-mesenchymal transition signature assessment in colorectal cancer quantifies tumour stromal content rather than true transition,’ in the journal The Journal of Pathology.

Ten-year follow-up after negative colonoscopies linked to lower colorectal cancer risk

Ten years after a negative colonoscopy, Kaiser Permanente members had 46 percent lower risk of being diagnosed with and were 88 percent less likely to die from colorectal cancer compared with those who did not undergo colorectal cancer screening, according to a study, ‘Long-term Risk of Colorectal Cancer and Related Deaths After a Colonoscopy With Normal Findings’, published in JAMA Internal Medicine.

Researchers develop personalised tool for inherited colorectal cancer syndrome

An international team of researchers led by Huntsman Cancer Institute (HCI) at the University of Utah (U of U) has developed, calibrated, and validated a novel tool for identifying the genetic changes in Lynch syndrome genes that are likely to be responsible for causing symptoms of the disease. The paper, ‘A functional assay–based procedure to classify mismatch repair gene variants in Lynch syndrome,’ was published in Genetics in Medicine

Loss of two genes drives a deadly form of colorectal cancer, revealing potential treatment

Scientists from Sanford Burnham Prebys Medical Discovery Institute (SBP), in collaboration with clinicians from Scripps Clinic, have identified that the loss of two genes drives the formation of serrated colorectal cancer, yielding potential biomarkers. The research has also identified a combination treatment that has treated the cancer in mice. The paper, ‘Simultaneous Loss of Both Atypical Protein Kinase C Genes in the Intestinal Epithelium Drives Serrated Intestinal Cancer by Impairing Immunosurveillance,’ was published in the journal Immunity.

Tailored lifestyle feedback during colorectal cancer screening improved health behaviours

A programme that provided individually tailored lifestyle recommendations for patients undergoing screening for colorectal cancer helped encourage healthy behaviour, according to results of a study’ Improving Cancer Preventive Behaviors: A Randomized Trial of Tailored Lifestyle Feedback in Colorectal Cancer Screening,’ published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.

Colon cancer cell switch helps evades treatment

Researchers in Germany have discovered that colon cancers are often resistant to existing drug treatments because they are composed of two different cell types that can replace each other when one cell type is killed. The study, 'Targeting tumor cell plasticity by combined inhibition of NOTCH and MAPK signaling in colon cancer', published in the Journal of Experimental Medicine, suggests that combination therapies targeting both cell types at once may be more effective at treating colorectal cancer, the third highest cause of cancer-related death in the United States.